April 26, 2022
Aperion Biologics create invIOs Holding through demerger
APEIRON Biologics AG has announced that the annual general meeting held yesterday has approved the new structure of the group…
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
April 22, 2022
Ultimovacs’ combination immunotherapies in cancer validated by the USPTO
Ultimovacs ASA has received a Notice of Allowance from the United States Patent and Trademarks Office (USPTO) concerning its US patent application 16/306,352 on the use of vaccine-checkpoint inhibitor combinations to treat cancer.
April 12, 2022
IO Biotech doses first patient in metastatic nsclc in phase 2, combining its candidate with Keytruda
IO Biotech, a clinical-stage biopharmaceutical company has dosed the first patient, in metastatic non-small cell lung cancer (NSCLC), in its…
April 11, 2022
Actinium Pharmaceuticals Highlights Potent Anti-Tumor Activity of a HER3 Targeted Radiotherapy at AACR
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), has announced positive results from preclinical studies evaluating an anti-HER3 antibody, conjugated with an Actinium-225 (Ac-225) radioisotope payload, for targeting HER3-positive non-small cell lung cancer (NSCLC) cells.
April 10, 2022
Three Year Follow-Up Data from Phase 3 CROWN Trial of Pfizer’s LORBRENA (lorlatinib) Confirm Prolonged Progression-Free Survival in First-Line ALK-Positive Advanced Lung Cancer
Pfizer Inc. (NYSE: PFE) announced updated results from the Phase 3 CROWN trial, which evaluated LORBRENA (lorlatinib, available in Europe under the brand name LORVIQUA) versus XALKORI (crizotinib) in people with previously untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
April 10, 2022
Affimed Presents Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at AACR Annual Meeting
Affimed N.V. (Nasdaq: AFMD) has provided a data update from the ongoing study of the company’s lead innate cell engager (ICE) AFM13 precomplexed with cord blood-derived natural killer (cbNK) cells.
April 7, 2022
Kizoo Portfolio Company Elastrin Therapeutics Inc. closes $10M Funding Round
Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform to develop therapeutics that render calcified tissue and organs supple again, has announced the closing of a $10 million funding round led by Kizoo Technology Capital, a early-stage investor in breakthrough rejuvenation technologies. Other investors in the round include Starbloom Capital and SC Launch.
April 7, 2022
IAVI and Moderna Partner to Tackle Broad Global Health Priorities Using mRNA for Vaccines and Antibodies
Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and the nonprofit scientific research organization IAVI have announced a new collaboration to employ mRNA technology to meet the challenge of a range of global health threats.
April 6, 2022
Sandoz Extends Collaboration Agreement with Ares Genetics to Drive Cutting-Edge Digital Solutions in Global Fight Against Antimicrobial Resistance (AMR)
Sandoz has announced the extension and expansion until January 31, 2025 of its strategic collaboration agreement with Ares Genetics (Ares), aimed at driving cutting-edge digital solutions in the global fight against antimicrobial resistance (AMR).
April 4, 2022
Moderna Launches New Charitable Foundation to Promote Public Health
Moderna, Inc. (NASDAQ:MRNA), has launched the Moderna Charitable Foundation to promote public health, access to quality healthcare and educational opportunities, particularly in underserved populations.